Northwell Health Awarded for Virtual Care Response During COVID-19 Pandemic

July 13, 2020

Northwell Health was awarded the Pandemic Acceleration and Activation Award from national telehealth leader Amwell®. Northwell Health is New York State’s largest health care provider and private employer.

Northwell Health was recognized for its swift virtual response to the coronavirus disease 2019 (COVID-19) pandemic, specifically its ability to enable quality health care to thousands in need through telehealth services.

“I am incredibly proud of the work done by the telehealth teams under extraordinary circumstances to make sure our patients could receive the care they needed from Northwell physicians and other members of our clinical teams too numerous to name,” said Dr. Martin Doerfler, MD, senior vice president of clinical strategy and development at Northwell.

Northwell’s telehealth program grew exponentially during the pandemic, integrating more than 65 departments into the scheduled visit workflow and increasing the number of providers on the Amwell system from a few hundred daily to over 5,000 virtual visits every day.

The ability to rapidly scale the virtual care program allowed Northwell to maintain care to patients, especially those in the most vulnerable populations. The program will remain a strong part of the way Northwell delivers care to patients in the future – not just during times of crisis, but regularly to those who would have difficulty accessing health care otherwise.

Northwell treated more COVID-19 patients than any other health system in the nation between March and June, including about 17,000 hospitalized patients. Accounting for those seen in the health system’s emergency departments, urgent care centers, physician practices and virtually, Northwell provided medical care to more than 55,000 COVID-19 patients overall.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version